Amalgamated Bank’s Quince Therapeutics QNCX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-16
Closed -$20K 3168
2022
Q1
$20K Buy
+16
New +$21.8K ﹤0.01% 2812
2021
Q4
Sell
-18
Closed -$325K 2173
2021
Q3
$325K Buy
+18
New +$286K ﹤0.01% 1811

Other funds holding QNCX

Amalgamated Bank's QNCX Position: Q2 2022 in Review

Amalgamated Bank sold out of Quince Therapeutics (QNCX) in Q2 2022, closing a stake of 16 shares — an estimated $20K sold.

Amalgamated Bank first reported a position in QNCX in Q3 2021 and held it in 2 quarters. The position peaked at $325K in Q3 2021. 66 funds tracked by Wall St. Rank hold QNCX as of Q2 2022.

  • Amalgamated Bank reported no remaining Quince Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Amalgamated Bank sold 16 Quince Therapeutics shares in Q2 2022, an estimated $20K.
  • Amalgamated Bank first reported a position in Quince Therapeutics in Q3 2021 and held it in 2 quarters.
  • Amalgamated Bank's Quince Therapeutics position peaked at $325K in Q3 2021.
  • 66 funds tracked by Wall St. Rank held Quince Therapeutics as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.